Advertisement

MMW - Fortschritte der Medizin

, Volume 161, Supplement 2, pp 42–46 | Cite as

Antiretrovirale Therapie

Geht der Trend nun zur Zweierkombination?

  • Hans HeikenEmail author
FORTBILDUNG . ÜBERSICHT
  • 15 Downloads

Die antiretrovirale Therapie basierte bislang auf der Kombination von drei Wirksstoffen aus zwei unterschiedlichen Substanzklassen. Mittlerweile wurden neue Daten aus großen Zulassungsstudien zur Therapie mit nur noch zwei Wirkstoffen präsentiert. Welches Potenzial haben Zweifachtherapien für den Einsatz in der Praxis?

Antiretroviral treatment for HIV: is it time for 2 drug regimens?

Keywords

HIV 2 drug regimen dual therapy dolutegravir rilpivirine SWORD GEMINI 

Literatur

  1. 1.
    Gueler A, Moser A, Calmy A et al. Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. AIDS 2017;31:427–36PubMedPubMedCentralGoogle Scholar
  2. 2.
    In: Deutsch-Österreichische Leitlinien zur antietroviralen Therapie der HIV-1-Infektion. AWMF 055-001, Version 7 v. 29.11.2017Google Scholar
  3. 3.
    Raffi F, Babiker AG, Richert L et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014;384(9958):1942–51CrossRefGoogle Scholar
  4. 4.
    Reynes J, Trinh R, Pulido F et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses. 2013;29(2):256–65CrossRefGoogle Scholar
  5. 5.
    Fabbiani M, Gagliardini R, Ciccarelli N et al. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. 2018;73(7):1955–64CrossRefGoogle Scholar
  6. 6.
    Perez-Molina JA, Rubio R, Rivero A et al. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015;15(7):775–84CrossRefGoogle Scholar
  7. 7.
    Arribas JR, Girard PM, Landman R et al. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015;15(7):785–92CrossRefGoogle Scholar
  8. 8.
    Llibre JM, Hung CC, Brinson C et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet 2018;391(10123):839–49CrossRefGoogle Scholar
  9. 9.
    Cahn P, Madero JS, Arribas JR et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143–55CrossRefGoogle Scholar
  10. 10.
    Figueroa M, Sued O, Gun A et al. DRV/R/3TC FDC for HIV-1 treatment naïve patients: week 48 results of the ANDES study. Conference on Retroviruses and Opportunistic Infections CROI, Boston 2018, Poster 489.Google Scholar
  11. 11.
    Margolis DA, Gonzalez-Garcia J, Stellbrink HJ et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499–1510CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Praxis Dres. Kuhlmann/Holm/HeikenHannoverDeutschland

Personalised recommendations